文献速递肿瘤 PET/CT放射性药物与辐射防护

用于表皮生长因子受体高表达肿瘤成像的64Cu标记重复体分子

64Cu-Labeled Repebody Molecules for Imaging of Epidermal Growth Factor Receptor-Expressing Tumors.
PubMed 文献 · J Nucl Med · 2017-09-15

本研究合成三种不同螯合剂(NOTA、DOTA、DTPA)偶联的抗表皮生长因子受体(EGFR)重复体,并用64Cu标记,在H1650(EGFR高表达)与SW620(EGFR低表达)细胞及H1650荷瘤小鼠中评估其生物学特性。三种64Cu-重复体在H1650细胞1小时的摄取均超过SW620细胞的4倍,静脉注射后1小时即在H1650肿瘤中特异性蓄积并滞留超过24小时,小动物PET可见清晰肿瘤显像。作者认为这些64Cu-重复体复合物可能在1小时内实现EGFR表达肿瘤的特异性快速摄取,有望作为新型EGFR PET显像剂。

要点

  • 三种64Cu标记重复体的放射化学产率约为70%-80%。
  • H1650细胞1小时摄取为SW620细胞的4倍以上。
  • 注射后1小时肿瘤特异性蓄积,滞留超过24小时,PET肿瘤清晰可见。

核心结论

  • 三种64Cu-重复体复合物在1小时内对EGFR表达肿瘤显示特异性快速摄取,可能作为新型EGFR PET显像剂。

研究设计与样本

  • 研究合成NOTA、DOTA、DTPA三种螯合剂偶联的抗EGFR重复体,并用64Cu标记。
  • 在H1650(EGFR高表达)与SW620(EGFR低表达)细胞中进行细胞摄取研究。
  • 在H1650荷瘤裸鼠中进行生物分布与小动物PET显像研究。

主要发现

  • 三种64Cu标记重复体的放射化学产率约为70%-80%。
  • 1小时时NOTA-、DOTA-、DTPA-重复体在H1650细胞的摄取均超过SW620细胞的4倍。
  • 静脉注射后1小时三种重复体在H1650荷瘤裸鼠中特异性蓄积,并滞留超过24小时(以%ID/g计)。
  • 肿瘤摄取从1小时至6小时增加:1小时NOTA-、DOTA-、DTPA-重复体分别为6.28、8.46、6.91 %ID/g;6小时分别为9.4、8.28、10.1 %ID/g。
  • 注射每种重复体后H1650肿瘤均清晰可见,肿瘤/背景比值较高:1小时NOTA-、DOTA-、DTPA-重复体分别为3.43、4.89、2.38;6小时分别为3.05、4.36、2.08;24小时分别为3.81、4.58、2.86。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The epidermal growth factor receptor (EGFR) is a member of the erbB family of receptors and is overexpressed in many tumor types. A repebody is a newly designed nonantibody protein scaffold for tumor targeting that contains leucine-rich repeat modules. In this study, 3 64Cu-labeled anti-EGFR repebodies with different chelators were synthesized, and their biologic characteristics were assessed in cultured cells and tumor-bearing mice. Methods: Repebodies were synthesized with the chelators 2-(p-isothiocyanatobenzyl)-1,4,7-triazacyclononane-N,N',N,″-triacetic acid trihydrochloride ([p-SCN-Bn]-NOTA), 2,2',2″-(10-(2-(2,5-dioxopyrrolidin-1-yloxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl) triacetic acid (DOTA-N-hydroxysuccinimide ester), or 1-(p-isothiocyanatobenzyl)diethylenetriamine pentaacetic acid trihydrochloride ([p-SCN-Bn]-DTPA) in 1.0 M NaHCO3 buffer (pH 9.2) for 24 h. Purified NOTA-, DOTA-, and DTPA-conjugated repebody were radiolabeled with 64Cu in 0.1 M NH4OAc buffer (pH 5.5). To compare the EGFR-binding affinities of the repebodies, cellular uptake studies were performed with the human non-small cell lung cancer cell line H1650 (high expression of EGFR) and the human colon adenocarcinoma cell line SW620 (low expression of EGFR). Biodistribution and small-animal PET imaging studies were performed using H1650 tumor-bearing mice. Results: Radiochemical yields of the 64Cu-labeled repebodies were approximately 70%-80%. Cellular uptake of the NOTA-, DOTA-, and DTPA-repebodies was over 4-fold higher in H1650 cells than in SW620 cells at 1 h. The 3 repebodies had accumulated specifically in H1650 tumor-bearing nude mice by 1 h after intravenous injection and were retained for over 24 h, as measured by the percentage injected dose per gram of tissue (%ID/g). Tumor uptake of all repebodies increased from 1 to 6 h (at 1 h, 6.28, 8.46, and 6.91 %ID/g for NOTA-, DOTA-, and DTPA-repebody, respectively; at 6 h, 9.4, 8.28, and 10.1 %ID/g, respectively). H1650 tumors were clearly visible after injection of each repebody, with high tumor-to-background ratios (at 1 h, 3.43, 4.89, and 2.38 for NOTA-, DOTA-, and DTPA-repebody, respectively; at 6 h, 3.05, 4.36, and 2.08; at 24 h, 3.81, 4.58, and 2.86). Conclusion: The 3 64Cu-repebody complexes demonstrated specific and rapid uptake in EGFR-expressing tumors within 1 h and may have potential as novel EGFR imaging agents for PET.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Pyo A, Yun M, Kim HS, et al. 64Cu-Labeled Repebody Molecules for Imaging of Epidermal Growth Factor Receptor-Expressing Tumors. J Nucl Med. 2017. PMID: 28916621. doi:10.2967/jnumed.117.197020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。